Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.typeArtigo de periódicopt_BR
dc.titleClinical Effects Of A4889g And T6235c Polymorphisms In Cytochrome P-450 Cyp1a1 For Breast Cancer Patients Treated With Tamoxifen: Implications For Tumor Aggressiveness And Patient Survival.pt_BR
dc.contributor.authorCardoso-Filho, Cassiopt_BR
dc.contributor.authorSarian, Luis Otaviopt_BR
dc.contributor.authorde Oliveira, Camila Borges Martinspt_BR
dc.contributor.authorda Silveira Bossi, Leonardopt_BR
dc.contributor.authorLourenço, Gustavo Jacobpt_BR
dc.contributor.authorLima, Carmen Silvia Passospt_BR
dc.contributor.authorGurgel, Maria Salete Costapt_BR
unicamp.authorCassio Cardoso-Filho, Department of Obstetrics and Gynecology, Campinas State University, Campinas, São Paulo, Brazil. ccf@unicamp.brpt_BR Otavio Sarian,pt Borges Martins de Oliveira,pt da Silveira Bossi,pt Jacob Lourenço,pt Silvia Passos Lima,pt Salete Costa Gurgel,pt
dc.subjectAntineoplastic Agents, Hormonalpt_BR
dc.subjectBreast Neoplasmspt_BR
dc.subjectCytochrome P-450 Cyp1a1pt_BR
dc.subjectEuropean Continental Ancestry Grouppt_BR
dc.subjectFollow-up Studiespt_BR
dc.subjectMultivariate Analysispt_BR
dc.subjectPolymorphism, Single Nucleotidept_BR
dc.subjectProspective Studiespt_BR
dc.subjectSurvival Ratept_BR
dc.subjectTreatment Outcomept_BR
dc.description.abstractIndividual differences in cytochrome P-450 efficiency partly explain their variations in resistance to tamoxifen and estrogen metabolism. Two polymorphisms of the CYP1A1 gene-A4889G and T6235C-are known to affect activation of estrone and estradiol and to deregulate concentration of highly active tamoxifen metabolites. However, the clinicopathologic implications of these findings have not yet been evaluated. The objective of this study is to evaluate whether T6235C and A4889G gene polymorphisms are related to pathological presentations and clinical outcomes of ER+/PR+ breast cancer (BC) in women using tamoxifen. We included 405 women with ER+/PR+ tumors, who used tamoxifen as their primary therapy, and for whom 5-year follow-up data were available. We evaluated associations within clinicopathologic features, including overall 5-year survival, with CYP1A1 gene status. Univariate analysis showed that a slightly higher proportion of women with AG/GG genotypes were of European descent (P = 0.05) and that TC/CC genotype was significantly associated with premenopausal status (P = 0.01); however, no significant association remained after multivariate adjustment. Women with CYP1A1 genotypes other than AA and TT were more prone to develop low-grade tumors; 85.9 % of tumors in AA and TT genotype groups were grade III, but only 76.1 % of tumors in carriers of the polymorphisms were grade III (adjusted P = 0.02; OR 0.51 for grade III disease; 95 % CI 0.28-0.93). After 60 months of follow-up, ~75 % of the women were alive. There was no significant difference in survival related to the CYP1A1 gene status. Breast cancer patients carrying CYP1A1 gene polymorphisms developed less aggressive tumors, but showed no evidence of better prognoses.en
dc.relation.ispartofCancer Chemotherapy And Pharmacologypt_BR
dc.relation.ispartofabbreviationCancer Chemother. Pharmacol.pt_BR
dc.identifier.citationCancer Chemotherapy And Pharmacology. v. 72, n. 3, p. 529-35, 2013-Sep.pt_BR
dc.description.provenanceMade available in DSpace on 2015-11-27T13:31:56Z (GMT). No. of bitstreams: 1 pmed_23842721.pdf: 229859 bytes, checksum: e855e29da9385e6818864677f04d09ba (MD5) Previous issue date: 2013en
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_23842721.pdf224.47 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.